Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts

Ashley L. Hilchie; David M. Conrad; Melanie R. Power Coombs; Tyler Zemlak; Carolyn D. Doucette; Robert S. Liwski; David W. Hoskin

doi:10.3109/10428194.2013.770847

Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts

Ashley L. Hilchie, David M. Conrad, Melanie R. Power Coombs, Tyler Zemlak, Carolyn D. Doucette, Robert S. Liwski, David W. Hoskin

Medicine

Résultat de recherche: Article › examen par les pairs

27 Citations (Scopus)

Résumé

Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens. The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. We demonstrate here that NRC-03 and NRC-07 bound to and rapidly killed multiple myeloma cells by causing extensive membrane damage, as well as DNA cleavage. NRC-03 showed greater binding to multiple myeloma cells and a more potent cytotoxic effect than NRC-07. In addition, intratumoral injections of NRC-03 impaired the growth of multiple myeloma xenografts in immune-deficient mice. We conclude that NRC-03 warrants further investigation for its possible use in the treatment of multiple myeloma.

Langue d'origine	English
Pages (de-à)	2255-2262
Nombre de pages	8
Journal	Leukemia and Lymphoma
Volume	54
Numéro de publication	10
DOI	https://doi.org/10.3109/10428194.2013.770847
Statut de publication	Published - oct. 2013

Note bibliographique

Funding Information:
Th is work was supported by a Capital Health Research Grant. A.H. and C.D. were supported by Postgraduate Scholarships from NSERC. D.C. was supported by a Dalhousie University Faculty of Medicine Summer Fellowship. T.Z. is supported by a trainee award from The Beatrice Hunter Cancer Research Institute with funds provided by Cancer Care Nova Scotia as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR. We thank Susan Douglas and Aleksander Patrzykat (Institute for Marine Biosciences, National Research Council) for helpful discussions, and Tony Reiman (Saint John Regional Hospital) for providing the human multiple myeloma cell lines. We also acknowledge the support of the Canada Foundation for Innovation, the Atlantic Innovation Fund, NSERC, and other partners that fund the Facilities for Materials Characterization, managed by the Institute for Research in Materials.

ASJC Scopus Subject Areas

Hematology
Oncology
Cancer Research

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

ODD de l’ONU

Cette action contribue à la réalisation des objectifs de développement durable suivants

Accès au document

10.3109/10428194.2013.770847

Autres fichiers et liens

Citer

@article{b8b849e13fe54c02a412bed0beb4c0ec,

title = "Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts",

abstract = "Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens. The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. We demonstrate here that NRC-03 and NRC-07 bound to and rapidly killed multiple myeloma cells by causing extensive membrane damage, as well as DNA cleavage. NRC-03 showed greater binding to multiple myeloma cells and a more potent cytotoxic effect than NRC-07. In addition, intratumoral injections of NRC-03 impaired the growth of multiple myeloma xenografts in immune-deficient mice. We conclude that NRC-03 warrants further investigation for its possible use in the treatment of multiple myeloma.",

author = "Hilchie, {Ashley L.} and Conrad, {David M.} and {Power Coombs}, {Melanie R.} and Tyler Zemlak and Doucette, {Carolyn D.} and Liwski, {Robert S.} and Hoskin, {David W.}",

note = "Funding Information: Th is work was supported by a Capital Health Research Grant. A.H. and C.D. were supported by Postgraduate Scholarships from NSERC. D.C. was supported by a Dalhousie University Faculty of Medicine Summer Fellowship. T.Z. is supported by a trainee award from The Beatrice Hunter Cancer Research Institute with funds provided by Cancer Care Nova Scotia as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR. We thank Susan Douglas and Aleksander Patrzykat (Institute for Marine Biosciences, National Research Council) for helpful discussions, and Tony Reiman (Saint John Regional Hospital) for providing the human multiple myeloma cell lines. We also acknowledge the support of the Canada Foundation for Innovation, the Atlantic Innovation Fund, NSERC, and other partners that fund the Facilities for Materials Characterization, managed by the Institute for Research in Materials.",

year = "2013",

month = oct,

doi = "10.3109/10428194.2013.770847",

language = "English",

volume = "54",

pages = "2255--2262",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts

AU - Hilchie, Ashley L.

AU - Conrad, David M.

AU - Power Coombs, Melanie R.

AU - Zemlak, Tyler

AU - Doucette, Carolyn D.

AU - Liwski, Robert S.

AU - Hoskin, David W.

N1 - Funding Information: Th is work was supported by a Capital Health Research Grant. A.H. and C.D. were supported by Postgraduate Scholarships from NSERC. D.C. was supported by a Dalhousie University Faculty of Medicine Summer Fellowship. T.Z. is supported by a trainee award from The Beatrice Hunter Cancer Research Institute with funds provided by Cancer Care Nova Scotia as part of the Terry Fox Strategic Health Research Training Program in Cancer Research at CIHR. We thank Susan Douglas and Aleksander Patrzykat (Institute for Marine Biosciences, National Research Council) for helpful discussions, and Tony Reiman (Saint John Regional Hospital) for providing the human multiple myeloma cell lines. We also acknowledge the support of the Canada Foundation for Innovation, the Atlantic Innovation Fund, NSERC, and other partners that fund the Facilities for Materials Characterization, managed by the Institute for Research in Materials.

PY - 2013/10

Y1 - 2013/10

N2 - Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens. The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. We demonstrate here that NRC-03 and NRC-07 bound to and rapidly killed multiple myeloma cells by causing extensive membrane damage, as well as DNA cleavage. NRC-03 showed greater binding to multiple myeloma cells and a more potent cytotoxic effect than NRC-07. In addition, intratumoral injections of NRC-03 impaired the growth of multiple myeloma xenografts in immune-deficient mice. We conclude that NRC-03 warrants further investigation for its possible use in the treatment of multiple myeloma.

AB - Multiple myeloma is a common hematological malignancy that urgently requires new approaches to treatment, since the disease is not curable using current chemotherapeutic regimens. The aim of this study was to determine whether human and mouse multiple myeloma cells are killed by the pleurocidin-like cationic antimicrobial peptides NRC-03 and NRC-07, previously shown to be active against breast cancer cells. We demonstrate here that NRC-03 and NRC-07 bound to and rapidly killed multiple myeloma cells by causing extensive membrane damage, as well as DNA cleavage. NRC-03 showed greater binding to multiple myeloma cells and a more potent cytotoxic effect than NRC-07. In addition, intratumoral injections of NRC-03 impaired the growth of multiple myeloma xenografts in immune-deficient mice. We conclude that NRC-03 warrants further investigation for its possible use in the treatment of multiple myeloma.

UR - http://www.scopus.com/inward/record.url?scp=84884478109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884478109&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.770847

DO - 10.3109/10428194.2013.770847

M3 - Article

C2 - 23350892

AN - SCOPUS:84884478109

SN - 1042-8194

VL - 54

SP - 2255

EP - 2262

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Pleurocidin-family cationic antimicrobial peptides mediate lysis of multiple myeloma cells and impair the growth of multiple myeloma xenografts

Résumé

Note bibliographique

ASJC Scopus Subject Areas

PubMed: MeSH publication types

ODD de l’ONU

Accès au document

Autres fichiers et liens

Empreinte numérique

Citer